Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer

Figure 1

Expression of RR subunits in liver cancer and cancer cell lines. (a) mRNA expression levels of RRM1, RRM2, and RRM2B between liver cancer (tumor) and adjacent nonmalignant liver tissue (normal) in The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) cohort. (b) mRNA expression levels of RRM1, RRM2, and RRM2B in paired tumor and adjacent nonmalignant (normal) tissues from TCGA-LIHC cohort. (c) mRNA expression levels of RRM1 among various liver cancer cohorts in the Hepatocellular Carcinoma Expression Atlas Database (HCCDB). (d) mRNA expression levels of RRM2 among various liver cancer cohorts in the HCCDB. (e) mRNA expression levels of RRM2B among various liver cancer cohorts in the HCCDB. (f) mRNA expression levels of RRM1 in a variety of liver cancer cell lines from Cancer Cell Line Encyclopedia (CCLE). (g) mRNA expression levels of RRM2 in a variety of liver cancer cell lines from CCLE. (h) mRNA expression levels of RRM2B in a variety of liver cancer cell lines from CCLE. and . The “ns” stands for “not significant”.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)